Startup · $32m raised
Sydney, NSW
Every investor coverage indicates participated in a round sunshineHeart raised.
| Investor | Rounds | Invested |
|---|---|---|
| Aspire Capital Fund, LLC | Unnamed stage | - |
| Commercial Ready | Grant | - |
Investors whose own portfolio pages list sunshineHeart, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Talu Ventures | its portfolio page ↗ |
The transaction that ended sunshineHeart's run as a startup, per published coverage. It closes the funding history too, where it is the ladder's last rung.
| Bought by | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| - | IPO | Sep 2004 | - | GBS Ventures (Thu 14 Apr 2011), GBS Ventures (Fri 4 Feb 2011), GBS Ventures (Wed 16 May 2007) |
Companies sunshineHeart acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming sunshineHeart. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
The ASX and NASDAQ-listed heart device maker names an investment banking executive to its board, citing his deal experience, as it readies a key US trial and a European study.
GBS Ventures' news page points to an attached document announcing Sunshine Heart's appointment of Warren Watson to its board; the page itself carries only the headline and date.
GBS Ventures reposts a 2013 notice that Sunshine Heart signed a $25 million financing agreement with Aspire Capital Fund, with details only in an attached download.
Also GBS Ventures
Brief November 2012 notice reporting that Sunshine Heart won unconditional American regulator clearance to run a pivotal United States trial of its C-Pulse heart device, with detail left to an attached document.
A bare stub on GBS Ventures' site dated December 2011, pointing readers to a downloadable ASX announcement about Sunshine Hearts; the page itself gives no details of the announcement's contents.
A stub news post on GBS Ventures' site flagging that Sunshine Heart's feasibility trial findings were due for presentation at a cardiology conference, with an attached document available for download.
A brief 2011 post from GBS Ventures linking to an attached ASX announcement about early results from Sunshine Heart's C-Pulse feasibility trial, released by Ohio State.
A brief 2011 notice recording that Sunshine Heart brought in A$7.4 million through a two-part private placement, with the ASX filing attached for download.
Profile of Sunshine Heart's C-Pulse heart pump, its US trials and trial funding plans, recalling the failure of fellow Australian device maker Ventracor during the global financial crisis.
A short GBS Ventures news post from May 2011 pointing readers to an attached CEO update document about Sunshine Heart; the page itself gives no details.
A brief GBS Ventures notice pointing readers to an attached document about the stock exchange's query to Sunshine Heart over a recent movement in its share price.
Sunshine Heart's CEO letter to investors reviews 2010: an A$13.2 million financing, C-Pulse trial growth at newly added hospitals, two senior R&D hires, and a website revamp.
ASX-listed heart device firm Sunshine Heart appoints US medtech executive Paul Buckman to its board, which now spans eight directors across Australia and the United States.
Sunshine Heart has completed an A$9.5m rights issue, following a September placement of A$3.7m. Backers GBS Venture Partners and CM Capital took full entitlements plus shortfall; proceeds fund US trials and European approval.
Sunshine Heart has locked in A$3.7 million from US institutional investors via Summer Street, with a larger rights issue of up to A$11 million still planned pending shareholder backing at an October meeting.
Also GBS Ventures
Sunshine Heart's chief executive reports to shareholders on the C-Pulse trial: halfway through its US feasibility study, first two minimally invasive implants completed and new hospitals in Australia, Canada and the US joining.
A reposted ASX announcement from Sunshine Heart reports the first minimally invasive implant of its C-Pulse heart assist system, carried out in early June by a Louisville surgeon under a US FDA feasibility trial.
Sunshine Heart's C-Pulse heart-assist device has been implanted in a sixth trial patient, with Pennsylvania State University performing its first such procedure under US regulatory approval.
Sunshine Heart has completed a $1.75 million share placement and announced a rights issue, with about $4.65 million pledged so far, including cornerstone commitments from CM Capital and GBS Venture Partners.
Sunshine Heart announces that two female patients at Louisville's Jewish Hospital are the first US women implanted with its C-Pulse heart assist system in an FDA-approved 20-patient feasibility trial.
Medical device maker Sunshine Heart reports its first two American C-Pulse patients cleared three-month follow-ups, booked initial reimbursement revenue from an Ohio trial site, and outlines coming CE Mark and FDA steps.
Sunshine Heart's board will weigh ways to secure extra funding after starting its US heart device trial; finance chief Brian Bolton retires, with Rowena Hubble becoming company secretary.
Sunshine Heart reports the first two US implants of its C-Pulse heart assist device, performed at Ohio State under a 20-patient FDA-approved feasibility trial running across six American hospitals.
A 2009 GBS Ventures news stub whose only content is a download link to a document about Sunshine Heart's first implants of its Pulse device; the page itself states no deal, amount or people.
Sunshine Heart says a Kentucky hospital is the first US site cleared by an ethics board to join its FDA-approved C-Pulse heart failure trial, with patient enrolment expected once contracts are signed.
Sunshine Heart won complete US regulator clearance to run its first American trial of the C-Pulse heart device, having satisfied conditions attached to September's conditional clearance; enrolment of trial participants was anticipated that year.
Sunshine Heart has eliminated its chief operating officer role, with Victor Windeyer departing as the company restructures its St Leonards operation; chief technical officer Dr William Peters resumes managing development.
Board change at Sunshine Heart: Nicholas Callinan takes the chairman role at the October 2008 annual meeting as Malcolm McComas steps down from it but stays a director; Callinan's venture capital career is profiled.
Sunshine Heart says the US FDA approved a reimbursement category for its C-Pulse heart assist trial, opening Medicare reimbursement; it retained Quorum Consulting and expects patient enrollment at six US institutions in late 2008.
US regulators have conditionally cleared Sunshine Heart to begin its first American trial of the C-Pulse heart assist device in moderate heart failure patients, with enrollment at six institutions.
Sunshine Heart says the US regulator has conditionally cleared its first American trial of the C-Pulse heart assist device, with about twenty patients to enrol across six US hospitals from late 2008.
Sunshine Heart's medical director welcomes a US regulator panel's unanimous green light for Thoratec's Heartmate II, arguing his company's C-Pulse targets a larger, earlier-stage patient group.
Sunshine Heart announced Dr Richard Lin will step down from its board at the November 2007 AGM, with Three Arch Partners nominating Dr Conrad Wang to stand for election in his place.
Sunshine Heart's major shareholders CM Capital and GBS agreed a revised schedule for their $6 million share subscription, payable in two 2007 tranches with extra options, as the company seeks US trial approval.
Sunshine Heart's Sydney subsidiary has named Victor Windeyer general manager while he remains chief operating officer of the American-listed parent, overseeing Australian operations ahead of a planned United States clinical trial filing.
Sunshine Heart's CEO showcased its C-Pulse cardiac support technology at a US bioventures conference; backer CM Capital attended, and the medtech firm readied US feasibility trials for its second-generation system.
A heart-device company has finished building an updated portable driver for its C-Pulse therapy system with a US manufacturing partner, completing preclinical work ahead of an American trial and regulator filing planned for 2007.
Also GBS Ventures·GBS Ventures
ASX-listed heart device maker Sunshine Heart has finished training clinicians at six US hospitals ahead of its C-Pulse feasibility trial, planned to start later in 2007.
Medical device company Sunshine Heart has contracted US research organisation Alquest to manage its North American clinical trial of the C-Pulse heart assist device.
Sunshine Heart, an ASX-listed medical device company, appoints Brian Bolton as its chief financial officer and company secretary from April 2007, thanking interim CFO Steven Skinner, ahead of United States clinical trials.